Key takeaways
- AOD9604 is a synthetic peptide based on the tail end of human growth hormone, the region (amino acids 176 to 191) that carries the hormone's fat-burning activity.
- It was engineered to keep the lipolytic (fat-releasing) effect of growth hormone while leaving out the parts that raise blood sugar or drive general tissue growth.
- In animal models it consistently increased fat breakdown and fat oxidation and reduced weight gain, with effects tied to renewed activity of fat-handling pathways.
- Metabolic Pharmaceuticals took AOD9604 through a full program of human obesity trials. The peptide was safe and well tolerated, and early dosing produced more weight loss than placebo, though the largest trials did not reach their primary weight-loss endpoint.
- Newer work has looked beyond fat loss into cartilage repair, and the human evidence overall remains early, so any use is best explored with a qualified physician.
What is AOD9604?
AOD9604 is a synthetic peptide modeled on a small section of human growth hormone. Growth hormone is a large molecule with many jobs, and decades of research showed that its ability to break down fat lives in one specific stretch near the end of the chain, amino acids 176 to 191. AOD9604 reproduces that fat-active region, with a single extra amino acid added to stabilize it, so the name is often written as hGH fragment 176-191.
The idea behind the design is selectivity. Full growth hormone burns fat, but it also raises blood sugar and promotes general tissue growth, which limits how it can be used. By isolating just the fat-handling segment, researchers aimed for a molecule that keeps the metabolic upside without the rest of the hormonal load. That focus on fat metabolism is why AOD9604 has been studied mainly as a weight and body-composition compound.
How it works
The proposed mechanism centers on lipolysis, the process by which fat cells release stored fat to be burned for energy. In a 2000 study in Hormone Research, AOD9604 increased lipolytic activity in the fat tissue of obese rats and cut weight gain by more than half over the treatment period, pointing to a direct effect on how fat is mobilized.
A 2001 study in Endocrinology mapped the pathway in more detail. Both full growth hormone and AOD9604 reduced body weight and fat in obese mice and restored the activity of the beta-3 adrenergic receptor, a key switch for fat burning that is suppressed in obesity, back toward the levels seen in lean animals. When the same compounds were tested in mice engineered to lack that receptor, the long-term fat loss disappeared, which shows the receptor matters for the sustained effect. Interestingly, the acute boost in energy expenditure and fat oxidation still appeared even without the receptor, so AOD9604 seems to work through more than one route. A 2004 review in Current Opinion in Investigational Drugs pulled this profile together as the rationale for moving the compound into people.
What the animal evidence shows
The foundational evidence is preclinical and points in a consistent direction. Across rodent models, AOD9604 increased the release and oxidation of fat and limited weight gain, and it did so without the rise in blood sugar that comes with whole growth hormone. The 2001 Endocrinology work is the clearest example, linking the weight and fat reductions to renewed beta-3 adrenergic receptor activity and a measurable jump in fat oxidation.
More recent animal research has explored a second use entirely. A 2015 study in the Annals of Clinical and Laboratory Science tested AOD9604 injected directly into the knee in a rabbit osteoarthritis model. AOD9604 combined with hyaluronic acid protected cartilage better than either treatment alone, with lower cartilage-damage scores and a shorter period of lameness. That hints at a tissue-repair role for the peptide beyond its original metabolic purpose, though this work is at an early animal stage.
Human trials
AOD9604 stands out among research peptides because it was carried into a real clinical program rather than staying in the lab. Metabolic Pharmaceuticals ran a series of human obesity trials, including a Phase IIb randomized, double-blind, placebo-controlled study of oral AOD9604 tablets in obese adults (ACTRN12605000067673). A 2014 safety review in the Journal of Endocrinology and Metabolism summarized the program as roughly six human trials covering about 600 obese adults.
The headline finding on safety is encouraging: across the trials AOD9604 was safe and well tolerated, with no serious adverse events attributed to the peptide. On weight loss the picture is more measured. Early and smaller dosing groups lost noticeably more weight than placebo, but the largest, longer trials did not reach statistical significance over placebo at their primary endpoint, which is why the company stopped developing it as an obesity drug. AOD9604 later received generally-recognized-as-safe status for use as a food and supplement ingredient, a regulatory acknowledgment of its strong human safety record.
Where it is being studied
Interest in AOD9604 today runs along two tracks. The original track is metabolic, where the strong safety data and the clean lipolytic mechanism keep it in the conversation around body composition and fat metabolism. The newer track is musculoskeletal, building on the rabbit cartilage findings and broader interest in peptides for tissue repair. A 2026 review in Sports Medicine placed AOD9604 among the peptides studied for musculoskeletal and metabolic outcomes, noting that animal results are favorable while rigorous human data in this newer area are still limited.
The overall arc is unusual and useful: a well-characterized mechanism, a clear safety profile established in hundreds of people, and active animal evidence opening a second potential application. Whether AOD9604 fits any individual goal is a question for a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed, ClinicalTrials registries, and peer-reviewed journals). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. AOD9604 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.